CD103 is a nanoparticulate formulation that slowly releases doxorubicine in a controlled fashion. Its main features are:
- Application in therapeutic areas including various (non-)solid tumours
- Enhanced toxicology profile compared to current market, allowing higher dosages
- Sustained exposure for improved therapeutic efficacy as compared to free doxorubicine
- Additionally improved therapeutic efficacy when targeted nanoparticles are used
Doxorubicin is a potent cytostatic agent with currently suffers from myocardial side effects as the major disadvantage. The controllable release profile is proven while recently the therapeutic efficacy is clearly demonstrated in a tumour mouse model.
For prospective licensing partners, an extensive data package is available. Please use our contact page to request more information.